QIAGEN Receives U.S. FDA EUA for QIAstat-Dx test kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus
Qiagen N.V. Common Shares (QGEN)
Last qiagen n.v. common shares earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corporate.qiagen.com/investor-relations
Company Research
Source: Business Wire
First syndromic testing solution to be deployed in epidemic can differentiate novel coronavirus from 21 other serious respiratory infectionsQIAstat-Dx Respiratory SARS-CoV-2 Panel delivers results in about one hourAdds an important tool for clinicians as part of QIAGEN’s global mobilization to scale up testing supplies for the COVID-19 response GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for use in diagnosing patients infected with the novel COVID-19 coronavirus.The QIAstat-Dx test kit can differentiate the SARS-CoV-2 coronavirus from 21 other serious respiratory infections in patients who may have similar symptoms in a single testing run of about one hour. It is a multiplexed nucleic acid test that evaluates samples such as nasopharyngea
Show less
Read more
Impact Snapshot
Event Time:
QGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QGEN alerts
High impacting Qiagen N.V. Common Shares news events
Weekly update
A roundup of the hottest topics
QGEN
News
- Colorado's Life Sciences Ecosystem Raised $2.15 Billion in 2024 [Yahoo! Finance]Yahoo! Finance
- QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological DataBusiness Wire
- Genotyping Market Size Estimated to be Worth USD 154.35 Billion by 2031, at 22.5% CAGR: The Insight Partners [Yahoo! Finance]Yahoo! Finance
- Qiagen (NYSE: QGEN) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $54.00 price target on the stock, up previously from $42.00.MarketBeat
- QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements [Yahoo! Finance]Yahoo! Finance
QGEN
Earnings
- 11/6/24 - Beat
QGEN
Sec Filings
- 11/8/24 - Form SC
- 11/8/24 - Form 6-K
- 11/8/24 - Form 6-K
- QGEN's page on the SEC website